LegoChem Biosciences has entered a research collaboration and license agreement with Takeda for the development of antibody-drug conjugates (ADCs) in immuno-oncology.
 
Takeda gains certain rights to LegoChemi’s ADC technology, ConjuAll, including its proprietary linker and conjugation platform, to research, develop and commercialize targeted immuno-oncology therapeutics. Under the terms of the agreement, Takeda has rights to use the LegoChem technology to develop therapeutics directed to up to three undisclosed targets.
 
LegoChem will receive $7.25 million in upfront and near-term milestone payments. In addition, LegoChem is eligible to receive development, regulatory and commercial milestone payments of up to $404 million as well as royalties on the sales of any resulting ADC products.
 
“We are delighted to collaborate with Takeda given its experience and expertise in oncology research and development. We believe this partnership provides further validation of our proprietary ADC platform technology that can be used for different oncology applications including immuno-oncology therapeutics,” said Yong-Zu Kim, chief executive officer, LegoChem Biosciences. “Our goal is to demonstrate the competitiveness of LegoChem in the global ADC market by applying our linker and payload platform technologies to our own and our collaborators’ pipelines.”